ReviewPituitary2018
Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma).
Review in Pituitary, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 46 citations in OpenAlex.
- The landscape of germline variants in breast and colorectal cancer susceptibility genes in patients with pituitary tumours.Journal of neuro-oncology · 2025Article
- The 2022 WHO classification of tumors of the pituitary gland: An update on aggressive and metastatic pituitary neuroendocrine tumors.Brain pathology (Zurich, Switzerland) · 2025Review
- Clinical presentation and recurrence of pituitary neuroendocrine tumors: results from a single referral center in Colombia.Journal of endocrinological investigation · 2023Article
- Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to Treatment.The Journal of clinical endocrinology and metabolism · 2023Article
- Recent Therapeutic Advances in Pituitary Carcinoma.Journal of immunotherapy and precision oncology · 2023Review
- The evolution in pituitary tumour classification: a clinical perspective.Endocrine oncology (Bristol, England) · 2023Review
- Pituitary Carcinoma Diagnosis and Survival Improvement, with Affordable Care Act Correlation: A SEER Database Study.Journal of neurological surgery. Part B, Skull base · 2022Article
- Tamoxifen Exerts Anticancer Effects on Pituitary Adenoma Progression via Inducing Cell Apoptosis and Inhibiting Cell Migration.International journal of molecular sciences · 2022Article
- An Update on Silent Corticotroph Adenomas: Diagnosis, Mechanisms, Clinical Features, and Management.Cancers · 2021Review
- Peptide Receptor Radionuclide Therapy and Primary Brain Tumors: An Overview.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Challenges in the Diagnosis of Pituitary Neuroendocrine Tumors.Endocrine pathology · 2021Article
- Case Report: Radioactive Holmium-166 Microspheres for the Intratumoral Treatment of a Canine Pituitary Tumor.Frontiers in veterinary science · 2021Article
- Phosphorylated EGFR (pEGFR T693) as a Novel Predictor of Recurrence in Non-Functioning Pituitary Adenomas.Frontiers in endocrinology · 2021Article
- Review
- The epidemiology of aggressive pituitary tumors (and its challenges).Reviews in endocrine & metabolic disorders · 2020Review
- A Population-Level Analysis of Pituitary Carcinoma from the National Cancer Database.Journal of neurological surgery. Part B, Skull base · 2020Article
- Contemporary Management of Clinically Non-functioning Pituitary Adenomas: A Clinical Review.Clinical medicine insights. Endocrinology and diabetes · 2020Review
- Regulating the CCNB1 gene can affect cell proliferation and apoptosis in pituitary adenomas and activate epithelial-to-mesenchymal transition.Oncology letters · 2019Article
- Lower all-cause mortality rates in patients harboring pituitary carcinoma following the introduction of temozolomide.Endocrine · 2019Article
- An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors.Endocrine pathology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-functioning pituitary carcinomas (NFPC) are defined as tumours of adenophyseal origin with craniospinal or systemic dissemination, with the absence of a hormonal hypersecretion syndrome. These are a histologically heterogenous group of tumours, comprising gonadotroph, null cell, "silent" tumours of corticotroph, somatotroph or lactotroph cell lineages as well as plurihormonal Pit-1 tumours. NFPC are exceedingly rare, and hence few cases have been described. This review has identified 38 patients with NFPC reported in the literature. Recurrent invasive non-functioning pituitary adenomas (NFPA) were observed in a majority of patients. Various factors have been identified as markers of the potential for aggressive behaviour, including rapid tumour growth, growth after radiotherapy, gain or shift of hormone secretion and raised proliferative markers. Typically, there is a latency of several years from the original presentation with an NFPA to identification of metastases and only 5 cases reported with rapidly progressive malignant disease within 1 month of presentation. Therapeutic options include debulking surgery, radiation therapy and chemotherapy with temozolomide recommended as first line systemic treatment. Although long-term survivors are described, prognosis remains generally very poor (median survival 8 months). Improvements in molecular tumour profiling may assist in predicting tumour behaviour, guide therapeutic choices and identify novel therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.